Cargando…
Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
BACKGROUND AND OBJECTIVES: Dorzagliatin is a first-in-class small molecule glucokinase activator (GKA) that improves pancreatic insulin secretion behavior and regulates hepatic glucose conversion in a glucose concentration-dependent manner. The primary objective of this study was to develop a popula...
Autores principales: | Wang, Kun, Feng, Lingge, Zhang, Jiayi, Zou, Quanfei, Xu, Fengyan, Sun, Zhongyi, Tang, Fuxing, Chen, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520121/ https://www.ncbi.nlm.nih.gov/pubmed/37537410 http://dx.doi.org/10.1007/s40262-023-01286-8 |
Ejemplares similares
-
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
por: Chen, Li, et al.
Publicado: (2023) -
Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
por: Yu, Yunfeng, et al.
Publicado: (2022) -
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
por: Miao, Jia, et al.
Publicado: (2021) -
Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020) -
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
por: Yang, Wenying, et al.
Publicado: (2022)